论文部分内容阅读
目的观察PCI术前口服血脂康对冠心病稳定型心绞痛患者介入治疗后心肌损伤标志物的影响。方法纳入冠心病稳定型心绞痛拟PCI治疗的患者74例,按照就诊顺序分为血脂康组(n=35例)和对照组(n=39例),血脂康组患者在术前在常规治疗的基础上口服血脂康1200mg/d共1周,对照组除未服血脂康外其他治疗均与血脂康组相同,两组患者分别于术前、术后10h、24h采集空腹静脉血3ml,对心肌损伤标志物:肌酸激酶同工酶MB(CK-MB),人心肌肌钙蛋白T(cardiac troponin T,CTnT),肌红蛋白(My-oglobin Myo)进行定量分析,并进行统计学处理。结果两组患者性别、年龄等临床资料相似无统计学差异,具有可比性,血脂康组CK-MB升高的患者所占比例显著低于对照组(11%对31%,P=0.044);两组cTnI升高的患者所占比例也差异显著(20%对46%,P=0.018);Myo虽然未表现出显著差异,但血脂康组与对照组相比也有降低趋势(23%对39%,P=0.127)。结论冠心病患者PCI术前预服血脂康可显著减少手术过程造成的心肌损伤。
Objective To observe the effect of oral administration of Xuezhikang before PCI on myocardial injury markers after interventional therapy in patients with coronary heart disease and stable angina pectoris. Methods Totally 74 patients were enrolled in the study. They were divided into Xuezhikang group (n = 35) and control group (n = 39) according to the order of treatment. The patients in Xuezhikang group were treated with conventional therapy On the basis of oral Xuezhikang 1200mg / d for 1 week, except for the control group without Xuezhikang other treatment are the same with Xuezhikang, two groups were preoperative and postoperative 10h, 24h collection of fasting venous blood 3ml, myocardial The injury markers, creatine kinase MB (CK-MB), cardiac troponin T (CTnT) and myoglobin Myo were quantitatively analyzed and statistically analyzed. Results There was no significant difference between the two groups in clinical data such as sex and age. The proportion of patients with elevated CK-MB in Xuezhikang group was significantly lower than that in control group (11% vs 31%, P = 0.044). There was also a significant difference in the proportion of patients with elevated cTnI between the two groups (20% vs. 46%, P = 0.018). Although Myo showed no significant difference, Xuezhikang also had a decreasing trend compared with the control group (23% vs. 39 %, P = 0.127). Conclusion Coronary heart disease before PCI preoperative Xuezhikang can significantly reduce the myocardial damage caused by surgery.